[1] SUNG H, FERLAY J, SIEGEL RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209. doi: 10.3322/caac.21660
[2] DIGKLIA A, WAGNER AD. Advanced gastric cancer: Current treatment landscape and future perspectives[J]. World J Gastroenterol, 2016, 22(8): 2403. doi: 10.3748/wjg.v22.i8.2403
[3] CREW KD, NEUGUT AL. Epidemiology of upper gastrointestinal malignancies[J]. Semin Oncol, 2004, 31(4): 450. doi: 10.1053/j.seminoncol.2004.04.021
[4] WANG Y, GAO W, SHI X, et al. Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin[J]. Nature, 2017, 547(7661): 99. doi: 10.1038/nature22393
[5] KOPALLI SR, KANG TB, LEE KH, et al. NLRP3 inflammasome activation inhibitors in inflammation-associated cancer immunotherapy: an update on the recent patents[J]. Recent Pat Anticancer Drug Discov, 2018, 13(1): 106.
[6] HUMPHRIES F, SHMUEL-GALIA L, KETELUT-CARNEIRO N, et al. Succination inactivates gasdermin D and blocks pyroptosis[J]. Science, 2020, 369(6511): 1633. doi: 10.1126/science.abb9818
[7] ERSHAID N, SHARON Y, DORON H, et al. NLRP3 inflammasome in fibroblasts links tissue damage with inflammation in breast cancer progression and metastasis[J]. Nat Commun, 2019, 10(1): 4375. doi: 10.1038/s41467-019-12370-8
[8] SHARIF H, WANG L, WANG WL, et al. Structural mechanism for NEK7-licensed activation of NLRP3 inflammasome[J]. Nature, 2019, 570(7761): 338. doi: 10.1038/s41586-019-1295-z
[9] REN G, ZHANG X, XIAO Y, et al. ABRO1 promotes NLRP3 inflammasome activation through regulation of NLRP3 deubiquitination[J]. EMBO J, 2019, 38(6): e100371.
[10] DUPAUL-CHICOINE J, ARABZADEH A, DAGENAIS M, et al. The Nlrp3 inflammasome suppresses colorectal cancer metastatic growth in the Liver by promoting natural killer cell tumoricidal activity[J]. Immunity, 2015, 43(4): 751. doi: 10.1016/j.immuni.2015.08.013
[11] LI S, LIANG X, MA L, et al. MiR-22 sustains NLRP3 expression and attenuates H. pylori-induced gastric carcinogenesis[J]. Oncogene, 2018, 37(7): 884. doi: 10.1038/onc.2017.381
[12] 任志, 马振增, 王启之. 幽门螺杆菌感染病人胃癌组织中MMP-7、VEGF的表达及相关性研究[J]. 蚌埠医学院学报, 2020, 45(6): 739.
[13] WAGNER EF, NEBREDA ÁR. Signal integration by JNK and p38 MAPK pathways in cancer development[J]. Nat Rev Cancer, 2009, 9(8): 537. doi: 10.1038/nrc2694
[14] LIM W, AN Y, YANG C, et al. Chrysophanol induces cell death and inhibits invasiveness via mitochondrial calcium overload in ovarian cancer cells[J]. J Cell Biochem, 2018, 119(12): 10216. doi: 10.1002/jcb.27363
[15] 王石健, 徐蒙娜, 汪佳兵. gasdermin D和gasdermin E介导的细胞焦亡在肿瘤中的研究进展[J]. 中国临床药理学与治疗学. 2020, 25(3): 352.
[16] KARKI R, MAN SM, KANNEGANTI TD. Inflammasomes and Cancer[J]. Cancer Immunol Res, 2017, 5(2): 94. doi: 10.1158/2326-6066.CIR-16-0269
[17] 康品方, 戎李, 孙硕等. 血清ALDH2和NLRP3活性水平在冠心病不同血管病变程度中的变化[J]. 蚌埠医学院学报. 2020, 45(7): 854.
[18] HE Y, ZENG MY, YANG D, et al. NEK7 is an essential mediator of NLRP3 activation downstream of potassium efflux[J]. Nature, 2016, 530(7590): 354. doi: 10.1038/nature16959
[19] TENG JF, MEI QB, ZHOU XG, et al. Polyphyllin Ⅵ induces caspase-1-mediated pyroptosis via the induction of ROS/NF-κB/NLRP3/GSDMD signal axis in non-small cell lung cancer[J]. Cancers(Basel), 2020, 12(1): 193.
[20] ZHANG CC, LI CG, WANG YF, et al. Chemotherapeutic paclitaxel and cisplatin differentially induce pyroptosis in A549 lung cancer cells via caspase-3/GSDME activation[J]. Apoptosis, 2019, 24(3/4): 312.
[21] YU J, LI S, QI J, et al. Cleavage of GSDME by caspase-3 determines lobaplatin-induced pyroptosis in colon cancer cells[J]. Cell Death Dis, 2019, 10(3): 193. doi: 10.1038/s41419-019-1441-4
[22] WU X, MAO X, HUANG Y, et al. Detection of proteins associated with the pyroptosis signaling pathway in breast cancer tissues and their significance[J]. Int J Clin Exp Pathol, 2020, 13(6): 1408.
[23] WANG Y, KONG H, ZENG X, et al. Activation of NLRP3 inflammasome enhances the proliferation and migration of A549 lung cancer cells[J]. Oncol Rep, 2016, 35(4): 2053. doi: 10.3892/or.2016.4569